[1]	Yin W, Wang J, Jiang L, et al. Cancer and stem cells[J]. Exp Biol Med (Maywood), 2021, 246(16):1791-1801.DOI:10.1177/15353702211005390. Cited in this article [1]

[2]	Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies:traditional to modern approaches to combat cancers[J]. Mol Biol Rep, 2023, 50(11):9663-9676.DOI:10.1007/s11033-023-08809-3. Cited in this article [1]

[3]	Petrov G, Dymova M, Richter V. Bacteriophage-mediated cancer gene therapy[J]. Int J Mol Sci, 2022, 23(22):14245.DOI:10.3390/ijms232214245. Cited in this article [4]

[4]	Kantoch M, Mordarski M. Binding of bacterial viruses by tumor cells in vitro[J]. Postepy Hig Med Dosw, 1958, 12(2):191-192. Cited in this article [2]

[5]	Saw PE, Song EW. Phage display screening of therapeutic peptide for cancer targeting and therapy[J]. Protein Cell, 2019, 10(11):787-807.DOI:10.1007/s13238-019-0639-7. Cited in this article [2]

[6]	El-Sayed A, Aleya L, Kamel M. Microbiota’s role in health and diseases[J]. Environ Sci Pollut Res Int, 2021, 28(28):36967-36983.DOI:10.1007/s11356-021-14593-z. Cited in this article [1]

[7]	Wang Q. Building personalized cancer therapeutics through multi-omics assays and bacteriophage-eukaryotic cell interactions[J]. Int J Mol Sci, 2021, 22(18):9712.DOI:10.3390/ijms22189712. Cited in this article [1]

[8]	Geier MR, Merril CR. Lambda phage transcription in human fibroblasts[J]. Virology, 1972, 47(3):638-643.DOI:10.1016/0042-6822(72)90553-3. Cited in this article [1]

[9]	Kabwe M, Dashper S, Bachrach G, et al. Bacteriophage manipulation of the microbiome associated with tumour microenvironments-can this improve cancer therapeutic response[J]. FEMS Microbiol Rev, 2021, 45(5):fuab017.DOI:10.1093/femsre/fuab017. Cited in this article [2]

[10]	Dabrowska K, Opolski A, Wietrzyk J, et al. Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of beta3 integrin signaling pathway[J]. Acta Virol, 2004, 48(4):241-248. Cited in this article [3]

[11]	Gorski A, Dabrowska K, Switala-Jeleń K, et al. New insights into the possible role of bacteriophages in host defense and disease[J]. Med Immunol, 2003, 2(1):2.DOI:10.1186/1476-9433-2-2. Cited in this article [3]

[12]	Wen S, Hou Y, Fu L, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling[J]. Cancer Lett, 2019, 442:320-332.DOI:10.1016/j.canlet.2018.10.015. Cited in this article [1]

[13]	Su X, Esser AK, Amend SR, et al. Antagonizing integrin β3 increases immunosuppression in cancer[J]. Cancer Res, 2016, 76(12):3484-3495.DOI:10.1158/0008-5472.Can-15-2663. Cited in this article [1]

[14]	Dabrowska K, Opolski A, Wietrzyk J, et al. Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models[J]. Anticancer Res, 2004, 24(6):3991-3995. Cited in this article [1]

[15]	Lehti TA, Pajunen MI, Skog MS, et al. Internalization of a polysialic acid-binding Escherichia coli bacteriophage into eukaryotic neuroblastoma cells[J]. Nat Commun, 2017, 8(1):1915.DOI:10.1038/s41467-017-02057-3. Cited in this article [1]

[16]	Monteiro R, Pires DP, Costa AR, et al. Phage therapy:going temperate[J]. Trends Microbiol, 2019, 27(4):368-378.DOI:10.1016/j.tim.2018.10.008. Cited in this article [2]

[17]	Kimchi O, Meir Y, Wingreen NS. Lytic and temperate phage naturally coexist in a dynamic population model[J]. ISME J, 2024, 18(1):wrae093.DOI:10.1093/ismejo/wrae093. Cited in this article [2]

[18]	Kirsch JM, Brzozowski RS, Faith D, et al. Bacteriophage-bacteria interactions in the gut:from invertebrates to mammals[J]. Annu Rev Virol, 2021, 8(1):95-113.DOI:10.1146/annurev-virology-091919-101238. Cited in this article [1]

[19]	Wahida A, Tang F, Barr JJ. Rethinking phage-bacteria-eukaryotic relationships and their influence on human health[J]. Cell Host Microbe, 2021, 29(5):681-688.DOI:10.1016/j.chom.2021.02.007. Cited in this article [1]

[20]	Wang Y, Fan H, Tong Y. Unveil the Secret of the Bacteria and Phage Arms Race[J]. Int J Mol Sci, 2023, 24(5).DOI:10.3390/ijms24054363. Cited in this article [1]

[21]	Laliani G, Ghasemian Sorboni S, Lari R, et al. Bacteria and cancer:different sides of the same coin[J]. Life Sci, 2020,246:117398.DOI:10.1016/j.lfs.2020.117398. Cited in this article [1]

[22]	Senchukova MA. Helicobacter pylori and gastric cancer progression[J]. Curr Microbiol, 2022, 79(12):383.DOI:10.1007/s00284-022-03089-9. Cited in this article [1]

[23]	Salvatori S, Marafini I, Laudisi F, et al. Helicobacter pylori and gastric cancer:pathogenetic mechanisms[J]. Int J Mol Sci, 2023, 24(3):2895.DOI:10.3390/ijms24032895. Cited in this article [1]

[24]	Samaras V, Rafailidis PI, Mourtzoukou EG, et al. Chronic bacterial and parasitic infections and cancer:a review[J]. J Infect Dev Ctries, 2010, 4(5):267-281.DOI:10.3855/jidc.819. Cited in this article [1]

[25]	Qin Y, Chen Y, Chen J, et al. The relationship between previous pulmonary tuberculosis and risk of lung cancer in the future[J]. Infect Agent Cancer, 2022, 17(1):20.DOI:10.1186/s13027-022-00434-2. Cited in this article [1]

[26]	Ai D, Pan H, Li X, et al. Identifying gut microbiota associated with colorectal cancer using a zero-inflated lognormal model[J]. Front Microbiol, 2019,10:826.DOI:10.3389/fmicb.2019.00826. Cited in this article [1]

[27]	Bala K, Husain I, Sharma A. Arginine deaminase from Pseudomonas aeruginosa PS2:purification,biochemical characterization and in-vitro evaluation of anticancer activity[J]. 3 Biotech, 2020, 10(5):226.DOI:10.1007/s13205-020-02212-6. Cited in this article [1]

[28]	Abdelaziz AA, Kamer AMA, Al-Monofy KB, et al. Pseudomonas aeruginosa’s greenish-blue pigment pyocyanin:its production and biological activities[J]. Microb Cell Fact, 2023, 22(1):110.DOI:10.1186/s12934-023-02122-1. Cited in this article [1]

[29]	Hetz C, Bono MR, Barros LF, et al. Microcin E492,a channel-forming bacteriocin from Klebsiella pneumoniae,induces apoptosis in some human cell lines[J]. Proc Natl Acad Sci U S A, 2002, 99(5):2696-2701.DOI:10.1073/pnas.052709699. Cited in this article [1]

[30]	Xu H, Luo H, Zhang J, et al. Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer[J]. Gut Microbes, 2023, 15(1):2186114.DOI:10.1080/19490976.2023.2186114. Cited in this article [1]

[31]	Jazeela K, Chakraborty A, Karunasagar I, et al. Nontyphoidal Salmonella:a potential anticancer agent[J]. J Appl Microbiol, 2020, 128(1):2-14.DOI:10.1111/jam.14297. Cited in this article [1]

[32]	Gutiérrez B, Domingo-Calap P. Phage therapy in gastrointestinal diseases[J]. Microorganisms, 2020, 8(9):1420.DOI:10.3390/microorganisms8091420. Cited in this article [1]

[33]	Shuwen H, Kefeng D. Intestinal phages interact with bacteria and are involved in human diseases[J]. Gut Microbes, 2022, 14(1):2113717.DOI:10.1080/19490976.2022.2113717. Cited in this article [3]

[34]	Nakatsu G, Zhou H, Wu WKK, et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes[J]. Gastroenterology, 2018, 155(2):529-541,e5.DOI:10.1053/j.gastro.2018.04.018. Cited in this article [2]

[35]	Li S, Liu J, Zheng X, et al. Tumorigenic bacteria in colorectal cancer:mechanisms and treatments[J]. Cancer Biol Med, 2021, 19(2):147-162.DOI:10.20892/j.issn.2095-3941.2020.0651. Cited in this article [1]

[36]	Hannigan GD, Duhaime MB, Ruffin MTT, et al. Diagnostic potential and interactive dynamics of the colorectal cancer virome[J]. mBio, 2018, 9(6):e02248-18.DOI:10.1128/mBio.02248-18. Cited in this article [1]

[37]	Rui R, Zhou L, He S. Cancer immunotherapies:advances and bottlenecks[J]. Front Immunol, 2023,14:1212476.DOI:10.3389/fimmu.2023.1212476. Cited in this article [1]

[38]	Van Belleghem JD, Dᶏbrowska K, Vaneechoutt M, et al. Interactions between bacteriophage,bacteria,and the mammalian immune system[J]. Viruses, 2018, 11(1):10.DOI:10.3390/v11010010. Cited in this article [1]

[39]	Gubin MM, Vesely MD. Cancer immunoediting in the era of immuno-oncology[J]. Clin Cancer Res, 2022, 28(18):3917-3928.DOI:10.1158/1078-0432.Ccr-21-1804. Cited in this article [1]

[40]	Kucharewicz-krukowska A, Slopek S. Immunogenic effect of bacteriophage in patients subjected to phage therapy[J]. Arch Immunol Ther Exp (Warsz), 1987, 35(5):553-561. Cited in this article [1]

[41]	Gogokhia L, Round JL. Immune-bacteriophage interactions in inflammatory bowel diseases[J]. Curr Opin Virol, 2021, 49:30-35.DOI:10.1016/j.coviro.2021.04.010. Cited in this article [1]

[42]	Jończyk-Matysia E, Weber-Dᶏbrowska B, Owczarek B, et al. Phage-phagocyte interactions and their implications for phage application as therapeutics[J]. Viruses, 2017, 9(6):150.DOI:10.3390/v9060150. Cited in this article [1]

[43]	Murgas P, Bustamante N, Araya N, et al. A filamentous bacteriophage targeted to carcinoembryonic antigen induces tumor regression in mouse models of colorectal cancer[J]. Cancer Immunol Immunother, 2018, 67(2):183-193.DOI:10.1007/s00262-017-2076-x. Cited in this article [1]

[44]	Fluckiger A, Daillère R, Sassi M, et al. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage[J]. Science, 2020, 369(6506):936-942.DOI:10.1126/science.aax0701. Cited in this article [1]

[45]	Pajtasz-Piasecka E, Rossowska J, Duś D, et al. Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma[J]. Immunol Lett, 2008, 116(1):24-32.DOI:10.1016/j.imlet.2007.11.004. Cited in this article [1]

[46]	Rojas G, Carmenate T, García-Pérez G, et al. Phagekines:directed evolution and characterization of functional cytokines displayed on phages[J]. Methods Mol Biol, 2023,2702:149-189.DOI:10.1007/978-1-0716-3381-6_8. Cited in this article [1]

[47]	Perea L, Rodríguez-Rubio L, Nieto JC, et al. Bacteriophages immunomodulate the response of monocytes[J]. Exp Biol Med (Maywood), 2021, 246(11):1263-1268.DOI:10.1177/1535370221995154. Cited in this article [1]

[48]	Thi HV, Ngo AD, Tran LT, et al. Phage for cancer therapy[J]. Prog Mol Biol Transl Sci, 2023, 201:225-239.DOI:10.1016/bs.pmbts.2023.03.015. Cited in this article [3]

[49]	Smith GP. Filamentous fusion phage:novel expression vectors that display cloned antigens on the virion surface[J]. Science, 1985, 228(4705):1315-1317.DOI:10.1126/science.4001944. Cited in this article [1]

[50]	Wang Y, Gao S, LV J, et al. Phage display technology and its applications in cancer immunotherapy[J]. Anticancer Age-nts Med Chem, 2019, 19(2):229-235.DOI:10.2174/1871520618666181029140814. Cited in this article [2]

[51]	Ma Z, Qin H, Chen H, et al. Phage display-derived oligopeptide-functionalized probes for in vivo specific photoacoustic imaging of osteosarcoma[J]. Nanomedicine, 2017, 13(1):111-121.DOI:10.1016/j.nano.2016.09.002. Cited in this article [1]

[52]	Liu Z, Gray BD, Barber C, et al. Characterization of TCP-1 probes for molecular imaging of colon cancer[J]. J Control Release, 2016, 239:223-230.DOI:10.1016/j.jconrel.2016,08,033. Cited in this article [1]

[53]	Yang X, Zhang F, Luo J, et al. A new non-muscle-invasive bladder tumor-homing peptide identified by phage display in vivo[J]. Oncol Rep, 2016, 36(1):79-89.DOI:10.3892/or.2016.4829. Cited in this article [1]

[54]	Mandelin J, Cardó-Vila M, Driessen WH, et al. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors[J]. Proc Natl Acad Sci U S A, 2015, 112(12):3776-3781.DOI:10.1073/pnas.1500128112. Cited in this article [1]

[55]	Yang C, He X, Liu X, et al. OSTP as a novel peptide specifically targeting human ovarian cancer[J]. Oncol Rep, 2015, 34(2):972-978.DOI:10.3892/or.2015.4066. Cited in this article [1]

[56]	Loi M, Di Paolo D, Soster M, et al. Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings[J]. J Control Release, 2013, 170(2):233-241.DOI:10.1016/j.jconrel.2013.04.029. Cited in this article [1]

[57]	Jiang Y, Yang N, Zhang H, et al. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition[J]. J Control Release, 2016, 221:26-36.DOI:10.1016/j.jconrel.2015.11.029. Cited in this article [1]

[58]	Choi H, Kim HD, Choi YW, et al. T7 phage display reveals NOLC1 as a GM3 binding partner in human breast cancer MCF-7 cells[J]. Arch Biochem Biophys, 2023,750:109810.DOI:10.1016/j.abb.2023.109810. Cited in this article [1]

[59]	Bar H, Yacoby I, Benhar I. Killing cancer cells by targeted drug-carrying phage nanomedicines[J]. BMC Biotechnol, 2008,8:37.DOI:10.1186/1472-6750-8-37. Cited in this article [1]

[60]	Deporter SM, Mcnaughton BR. Engineered M13 bacteriophage nanocarriers for intracellular delivery of exogenous proteins to human prostate cancer cells[J]. Bioconjug Chem, 2014, 25(9):1620-1625.DOI:10.1021/bc500339k. Cited in this article [1]

[61]	Smith TL, Yuan Z, Cardó-Vila M, et al. AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas[J]. Proc Natl Acad Sci U S A, 2016, 113(9):2466-2471.DOI:10.1073/pnas.1525709113. Cited in this article [1]

[62]	Ayat H, Burrone OR, Sadghizadeh M, et al. Isolation of scFv antibody fragments against HER2 and CEA tumor antigens from combinatorial antibody libraries derived from cancer patients[J]. Biologicals, 2013, 41(6):345-354.DOI:10.1016/j.biologicals.2013.05.004. Cited in this article [1]

[63]

Romani C, Cocco E, Bignotti E, et al. Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery[J]. Oncotarget, 2015, 6(33):34617-34628.DOI:10.18632/oncotarget.5315. Cited in this article [1]

[64]	Lin H, Zhang H, Wang J, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo[J]. Int J Cancer, 2014, 134(5):1239-1249.DOI:10.1002/ijc.28451. Cited in this article [1]

[65]	Dabrowska K, Skaradziński G, Jończyk P, et al. The effect of bacteriophages T4 and HAP1 on in vitro melanoma migration[J]. BMC Microbiol, 2009,9:13.DOI:10.1186/1471-2180-9-13. Cited in this article [1]

[66]	Dong X, Pan P, Zheng DW, et al. Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer[J]. Sci Adv, 2020, 6(20):eaba1590.DOI:10.1126/sciadv.aba1590. Cited in this article [1]

[67]	Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, et al. A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses[J]. Clin Exp Med, 2009, 9(4):303-312.DOI:10.1007/s10238-009-0044-2. Cited in this article [1]

[68]	Li J, Zheng H, Leung SSY. Potential of bacteriophage therapy in managing Staphylococcus aureus infections during chemotherapy for lung cancer patients[J]. Sci Rep, 2023, 13(1):9534.DOI:10.1038/s41598-023-36749-2. Cited in this article [1]

[69]	Abdul-Mutakabbir JC, Griffith NC, Shield RK, et al. Contemporary perspective on the treatment of acinetobacter baumannii infections:insights from the society of infectious diseases pharmacists[J]. Infect Dis Ther, 2021, 10(4):2177-2202.DOI:10.1007/s40121-021-00541-4. Cited in this article [1]

[70]	Lu J, Ding J, Liu Z, et al. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review)[J]. Int J Oncol, 2022, 60(2):12.DOI:10.3892/ijo.2022.5302. Cited in this article [1]

[71]	Hwang YJ, Myung H. Engineered bacteriophage T7 as a potent anticancer agent in vivo[J]. Front Microbiol, 2020,11:491001.DOI:10.3389/fmicb.2020.491001. Cited in this article [1]

[72]	Asavarut P, Waramit S, Suwan K, et al. Systemically targeted cancer immunotherapy and gene delivery using transmorphic particles[J]. EMBO Mol Med, 2022, 14(8):e15418.DOI:10.15252/emmm.202115418. Cited in this article [1]

[73]	Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy[J]. MAbs, 2016, 8(7):1177-1194.DOI:10.1080/19420862.2016.1212149. Cited in this article [1]

[74]	Petrenko VA. Landscape phage:evolution from phage display to nanobiotechnology[J]. Viruses, 2018, 10(6):311.DOI:10.3390/v10060311. Cited in this article [1]

[75]	Cesur-Ergün B, Demir-Dora D. Gene therapy in cancer[J]. J Gene Med, 2023, 25(11):e3550.DOI:10.1002/jgm.3550. Cited in this article [1]

[76]	Hajitou A, Trepel M, Lilley CE, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging[J]. Cell, 2006, 125(2):385-398.DOI:10.1016/j.cell.2006.02.042. Cited in this article [1]

[77]	Dobroff AS, D’Angelo S, Eckhardt BL, et al. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes[J]. Proc Natl Acad Sci U S A, 2016, 113(45):12780-12785.DOI:10.1073/pnas.1615288113. Cited in this article [1]

[78]	Chira S, Gulei D, Hajitou A, et al. Restoring the p53 ’guardian’ phenotype in p53-deficient tumor cells with CRISPR/Cas9[J]. Trends Biotechnol, 2018, 36(7):653-660.DOI:10.1016/j.tibtech.2018.01.014. Cited in this article [1]

[79]	Sanmukh SG, Dos Santos NJ, Barquilha CN, et al. Bacteriophages M13 and T4 increase the expression of anchorage-dependent survival pathway genes and down regulate androgen receptor expression in LNCaP prostate cell line[J]. Viruses, 2021, 13(9):1754.DOI:10.3390/v13091754. Cited in this article [1]

[80]	Hodyra-Stefaniak K, Miernikiew P, Drapała J, et al. Mammalian host-versus-phage immune response determines phage fate in vivo[J]. Sci Rep, 2015,5:14802.DOI:10.1038/srep14802. Cited in this article [1]

[81]	Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes[J]. Science, 2007, 315(5819):1709-1712.DOI:10.1126/science.1138140. Cited in this article [1]

[82]	Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms[J]. Nat Rev Microbiol, 2010, 8(5):317-327.DOI:10.1038/nrmicro2315. Cited in this article [1]

[83]	Federici S, Kredo-Russo S, Valdés-Mas R, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation[J]. Cell, 2022, 185(16):2879-2898.e24.DOI:10.1016/j.cell.2022.07.003. Cited in this article [1]

[84]	Doron S, Melamed S, Ofir G, et al. Systematic discovery of antiphage defense systems in the microbial pangenome[J]. Science, 2018, 359(6379):eaar4120.DOI:10.1126/science.aar4120.